This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
The FDA on Wednesday gave the thumbs up to a tablet formulation of Roche's Evrys...
Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super B...
Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super B...
More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Ad...
The FDA on Wednesday gave the thumbs up to a tablet formulation of Roche's Evrys...
In the last few years, Astellas has invested heavily in novel technologies that ...
Orchard Therapeutics has tasked Robin Kenselaar with accelerating growth of Lenm...
To guide children through an atypical hemolytic uremic syndrome diagnosis and su...
While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-...
In this tracker, Fierce Pharma is recording the regulatory progress of in-market...
In this tracker, Fierce Pharma is recording the regulatory progress of in-market...
The company's HIV sales surged 16% during the quarter, setting the scene for its...
After Merck KGaA's recent confirmation that it's in discussions to acquire Sprin...
So far in 2025, the year’s biggest cultural events have served as launchpads for...
The FDA earlier this month issued separate warning letters to Chinese drug ingre...
Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzhei...
During its quarterly earnings presentation, Vertex said that it expects to begin...
Oxford Cannabinoid Technologies is shedding its old skin. Having delisted its st...
Merck KGaA is in advanced talks to acquire cancer and rare disease specialist Sp...
New Hampshire’s Bio X Cell, which has made a name for itself over the past quart...
Older millennials, take note: Bayer is worried about your heart health. The drug...
Merck KGaA is in advanced talks to acquire cancer and rare disease specialist Sp...
Merck KGaA is in advanced talks to acquire cancer and rare disease specialist Sp...
Hims & Hers' “Sick of the System” spot not only generated the highest engagement...